Key result
Apixaban reduces bleeding events versus warfarin in dialysis patients while maintaining efficacy.
Why the study?
Does apixaban reduce bleeding events compared to warfarin in patients with ESRD maintained on dialysis?
Does apixaban reduce bleeding events compared to warfarin in patients with ESRD maintained on dialysis?
Apixaban may be a safer alternative to warfarin with fewer bleeding events in ESRD patients on dialysis.
Answers are grounded in this paper and cite their sources.
May support apixaban preference in ESRD dialysis; hypothesis-generating and should not yet change practice.
Compared to warfarin, our findings suggest that apixaban is a safe and effective alternative in patients with ESRD maintained on dialysis, with apixaban patients experiencing fewer bleeding events than warfarin patients.
No takes yet. Share an insight, caveat, or question.
Reed et al. (2018) studied this question. Apixaban is a safe and effective alternative to warfarin in patients with end-stage renal disease on dialysis, resulting in fewer bleeding events.
Synapse has enriched 10 related papers. Consider them for comparative context: